This pilot phase I trial studies how well rifaximin works in preventing infections and improving the balance of bacteria within the gut of participants with blood cancer who are undergoing blood and marrow transplantation. Rifaximin is an antibiotic used to treat intestinal infections by preventing bacteria from invading the intestinal wall. Giving rifaximin may help to prevent bacterial infections and improve transplant outcomes in participants undergoing hematopoietic stem cell transplantation.
Additional locations may be listed on ClinicalTrials.gov for NCT03529825.
Locations matching your search criteria
United States
Georgia
Atlanta
Children's Healthcare of Atlanta - Arthur M Blank HospitalStatus: Active
Contact: Muna Qayed
Phone: 404-785-1441
PRIMARY OBJECTIVE:
I. To describe the impact of rifaximin on gut microbiome diversity.
SECONDARY OBJECTIVE:
I. To estimate the rate of blood stream infections (BSI) in patients treated with rifaximin.
OUTLINE:
Participants receive rifaximin orally (PO) or enterally by gastric or naso-gastric/nasojejunal (NG/NJ) tube twice daily (BID) on day -7 or upon admittance to the hospital for hematopoietic stem cell transplantation (HSCT), whichever is later. Treatment continues for 28 days after HSCT or until discharge for a maximum of 36 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up on days 42 and 100, at 8 months, and at 1 year after HSCT.
Lead OrganizationChildren's Healthcare of Atlanta - Arthur M Blank Hospital
Principal InvestigatorMuna Qayed
